EU warns of brain tumour risk with some contraceptives
EU pharmaceutical safety advisers have said that commonly used contraceptives may carry a small risk of a type of brain cancer with prolonged use.
Newsletters and Deep Dive digital magazine
EU pharmaceutical safety advisers have said that commonly used contraceptives may carry a small risk of a type of brain cancer with prolonged use.
The desire for patients to be active partners in research challenges how organisations approach patient engagement.
A strong end-of-life care system does not wait until the final days to step in.
Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.
A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.
Editor's Picks
Newsletters and Deep Dive
digital magazine